Use the hyperlinks, where available to access additional clinical trial information.
A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
Deciphera Pharmaceuticals LLC
This trial consists of two phases:
(1) Dose Escalation Phase: Patients will receive increasing doses of DCC-3014, beginning at 10 mg once a day, for 28 day cycles until disease progression or unacceptable toxicity is experienced.(2) Expansion Phase: Patients will receive DCC-3014 at a dose level determined from the Dose Escalation Phase of the trial.